INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying several investigational drugs as a possible treatment for
Glioblastoma (GBM).
The drugs involved in this study are :
- Abemaciclib
- Temozolomide (temodar)
- Neratinib
- CC115
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute Patrick Y. Wen, MD
Collaborators:
Accelerate Brain Cancer Cure Celgene Eli Lilly and Company Puma Biotechnology, Inc.